Hepatitis C virus (HCV) will continue to be a serious global health threat for many years to come because of the chronic nature of the infection, its high prevalence and the significant morbidity of the resulting disease. Recently, a small number of molecules have produced encouraging results in proof-of-concept clinical trials. At the same time, preclinical evidence is accumulating that development of resistance will eventually limit the efficacy of new drugs. Thus, combinations of multiple agents will be required to treat chronic HCV infection.
Challenges and successes in developing new therapies for hepatitis C / R. De Francesco, G. Migliaccio. - In: NATURE. - ISSN 0028-0836. - 436:7053(2005), pp. 953-960.
Titolo: | Challenges and successes in developing new therapies for hepatitis C |
Autori: | |
Parole Chiave: | Dependent RNA-polymerase; virus serine-protease; small interfering RNAS; toll-like receptors; peptide-based inhibitors; in-vitro resistance; crystal-structure; NS3 protease; HCVNS5B polymerase; thiophene-2-carboxylic acids |
Settore Scientifico Disciplinare: | Settore BIO/14 - Farmacologia Settore BIO/19 - Microbiologia Generale |
Data di pubblicazione: | 2005 |
Rivista: | |
Tipologia: | Article (author) |
Digital Object Identifier (DOI): | http://dx.doi.org/10.1038/nature04080 |
Appare nelle tipologie: | 01 - Articolo su periodico |
File in questo prodotto:
File | Descrizione | Tipologia | Licenza | |
---|---|---|---|---|
De Francesco and Migliaccio.pdf | Publisher's version/PDF | Administrator Richiedi una copia |